🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

U.S. abortion providers relieved but wary as Supreme Court preserves pill access

Published 04/21/2023, 10:38 PM
Updated 04/22/2023, 01:45 AM
© Reuters. FILE PHOTO: Pro-abortion demonstrators gather at the State Capitol to mark the 50th anniversary of Roe v. Wade, the Supreme Court decision that had established a right to abortion until it was overturned last year, in Madison, Wisconsin, U.S. January 22,

By Sharon Bernstein

(Reuters) - Abortion rights supporters expressed relief on Friday after the U.S. Supreme Court preserved access to a widely used abortion pill but warned of a long fight ahead as a legal challenge to the medication continues.

The move by the court to halt new restrictions on the drug set by lower courts was welcome news less than a year after its conservative majority upended U.S. abortion access by overturning the landmark 1973 Roe v. Wade decision that had legalized abortion nationwide.

Abortion providers had been stockpiling the abortion pill mifepristone or planning to switch to a new regimen amid the battle over the legality of a drug used in more than half of U.S. abortions.

Several providers said late on Friday they would pause plans to change their medication abortion protocol in light of the Supreme Court's order.

"It’s the right decision and a huge relief," said Joshua Sharfstein, a public health professor at Johns Hopkins University and a former FDA official. "The alternative would have not only undermined access to reproductive health care, it would have thrown into disarray drug regulation in the United States."

Friday's order will allow mifepristone to remain available with no new restrictions while a court battle that could take months or longer plays out.

The Supreme Court did not rule on the merits of the case, however, meaning that mifepristone could still be restricted or banned at a later stage in the case.

Abortion opponents said on Friday they were confident the court ultimately would rule in favor of the pill's challengers, who contend that the FDA illegally approved mifepristone and then removed critical safeguards on what they call a dangerous drug.

"What the courts will see is a drug that does not cure a disease or alleviate the symptoms of a disease," said Carol Tobias, president of National Right to Life. "It was developed to take the life of an unborn child and always has the potential to harm the mother."

Several states where abortion remains legal, including California, Massachusetts and Washington, previously said they had begun stockpiling abortion drugs in advance of possible restrictions. Some Planned Parenthood clinics also said they had stockpiled at least a year's worth of mifepristone.

California and other liberal states have promised to protect pharmacists who continue to dispense mifepristone if it is prescribed by doctors, even if FDA approval is withdrawn.

Mifepristone is taken with another drug called misoprostol to perform medication abortion in the U.S.

Nicole Erwin, a spokesperson for Planned Parenthood Alliance Advocates and Planned Parenthood of the Great Northwest, Hawaii, Alaska, Indiana and Kentucky, said there was no longer an immediate reason to switch to a one-drug regimen using only misoprostol.

"The court ruled that access to mifepristone should remain unchanged while the case moves through lower courts, which means there is no need to move away from the current two-pill regimen," she said.

© Reuters. FILE PHOTO: Pro-abortion demonstrators gather at the State Capitol to mark the 50th anniversary of Roe v. Wade, the Supreme Court decision that had established a right to abortion until it was overturned last year, in Madison, Wisconsin, U.S. January 22, 2023.  REUTERS/Eric Cox

But reproductive rights supporters said they remained concerned about the future risks to access as the case returns to the lower courts that had sought to restrict it.

"We're still planning to stockpile both mifepristone and misoprostol just in case," said Josie Urbina, a physician specializing in complex pregnancy at the University of California, San Francisco, Center for Pregnancy Options.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.